Welcome to LookChem.com Sign In|Join Free

CAS

  • or

260562-59-2

5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

260562-59-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 260562-59-2 Structure

  • Basic information

    1. Product Name: 5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE
    2. Synonyms: 5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE
    3. CAS NO:260562-59-2
    4. Molecular Formula: C16H26N4O4Si
    5. Molecular Weight: 366.49
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 260562-59-2.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE(CAS DataBase Reference)
    10. NIST Chemistry Reference: 5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE(260562-59-2)
    11. EPA Substance Registry System: 5'-O-TERT-BUTYLDIMETHYLSILYL-2'-DEOXYINOSINE(260562-59-2)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 260562-59-2(Hazardous Substances Data)

260562-59-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 260562-59-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,0,5,6 and 2 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 260562-59:
(8*2)+(7*6)+(6*0)+(5*5)+(4*6)+(3*2)+(2*5)+(1*9)=132
132 % 10 = 2
So 260562-59-2 is a valid CAS Registry Number.

260562-59-2Relevant articles and documents

ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS

-

Paragraph 00470; 00483-00486, (2022/03/07)

Disclosed herein are 3, 4–didehydro- and 3′-deoxy-3, 4–didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, and BKV. P-595088-PC

Phosphonomethyl Oligonucleotides as Backbone-Modified Artificial Genetic Polymers

Liu, Chao,Cozens, Christopher,Jaziri, Faten,Rozenski, Jef,Maréchal, Amandine,Dumbre, Shrinivas,Pezo, Valérie,Marlière, Philippe,Pinheiro, Vitor B.,Groaz, Elisabetta,Herdewijn, Piet

supporting information, p. 6690 - 6699 (2018/05/15)

Although several synthetic or xenobiotic nucleic acids (XNAs) have been shown to be viable genetic materials in vitro, major hurdles remain for their in vivo applications, particularly orthogonality. The availability of XNAs that do not interact with natu

Synthesis and anti-HIV evaluation of 2',3'-dideoxy imidazo- and ν- triazolo[4,5-d]pyridazine nucleosides

Bussolari, Jacqueline C.,Panzica, Raymond P.

, p. 2373 - 2379 (2007/10/03)

The syntheses of the 2'-deoxy and 2',3'-dideoxynucleosides of 2,8-diaza- 3-deazainosine and the 2',3'-dideoxynucleoside of 2-aza-3-deazainosine were achieved and the pathways leading to these novel nucleosides are described. The preparation of the 2',3'-dideoxynucleoside (1) of 2-aza-3-deazainosine involved deoxygenation of the 2'-deoxy-3'-imidazolide intermediate with n- Bu3SnH and AIBN. The latter nucleoside was synthesized from the known 2'- deoxy derivative of 2-aza-3-deazainosine. The three-step synthesis of 1 from the 2'-deoxy analogue was accomplished in 40% overall yield. Rather than synthesize the corresponding 2',3'-dideoxynucleoside (2) of 2,8-diaza-3- deazainosine in the same manner, i.e. deoxygenation of the 2'- deoxynucleoside, a more cost-effective route was chosen. This pathway involved reductive cleavage of the 5'-protected, 2',3'-thiocarbonate derivative to furnish a mixture of the 2'- and 3'-deoxy isomers. This mixture was not separated, but was deoxygenated by the aforementioned imidazolide method. Using this methodology, 2 was prepared in 23% overall yield from 2,8- diaza-3-deazainosine. Nucleosides 1 and 2 were evaluated for antiretroviral activity and were found to be inactive. (C) 1999 Elsevier Science Ltd.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 260562-59-2